Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Reports 94-Percent Jump in Q3 Revenue, Though Losses Jump 10 Percent

NEW YORK, Oct. 21 (GenomeWeb News) - CombiMatrix today reported a 94-percent increase in third-quarter revenues atop a jump in R&D spending and widened net losses.

 

Total receipts for the period ended Sept. 30 increased to $1.5 million from $753,000 year over year, the Acacia unit reported. The brunt of the growth came from product sales and services, which increased to $490,000 in the third quarter 2005 from $68,000 in the prior year. Revenue from government contracts increased to $973,000 from $685,000.

 

R&D costs increased 34 percent to $1.5 million from $1.1 million in the year-ago period.

 

Net losses in the third quarter widened almost 10 percent to $3.9 million from $3.5 million, CombiMatrix said.

 

The unit had around $24.7 million in cash and short-term investments as of Sept. 30.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.